Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia

Trial Profile

Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2008

At a glance

  • Drugs Aripiprazole; Olanzapine
  • Indications Agitation; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Dec 2008 Results were published in the Journal of Clinical Psychopharmacology.
    • 11 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top